Stefan Frings M.D., Ph.D., became the Deputy Chief Medical Officer Pharma Development of Roche
Pharma in 2024 after he led for four years the Global Medical Affairs organization in Pharma
Development. Beforehand, he served as the Head of Strategy, Portfolio & Clinical Operations in
Roche Pharma Research and Early Development.

In his previous roles across Roche and Genentech, Stefan was the Country Medical Director of
Roche Pharma in Germany and held various leadership roles as Global Head of Oncology at Roche
Partnering, Global Head of Medical Affairs Oncology, Global Franchise Director for the Avastin and
earlier the HER2 Franchise and various Life Cycle Leader, International, and Local Medical Manager
positions. One highlight: As Research Development Team leader for pertuzumab, he was
instrumental for the successful development of this molecule in HER2-pos breast cancer and later
on as Global HER2-franchise lead in the work-up of the adjuvant BC program.

Before joining Roche in 1997, Stefan graduated from medical school in Germany where he gained a
board certification for internal medicine and underwent sub-specialty training in onco-
/hematology at the West German Cancer Centre and a large academic teaching hospital. He
obtained his Ph.D. for experimental work with SSEPs in patients undergoing carotid
endarterectomy in the vascular surgery department of the Heinrich Heine University in
Duesseldorf, Germany.